SLC5A2 and hydrops fetalis: Recently sodium-glucose cotransporter 2 inhibitors (SGLT-2) have joined this group, and according to current ESC guidelines blockade of the renin-angiotensin-aldosterone system with ACE, ARNI or ARB, beta-blocker, SGLT-2 inhibitor and MRA should be started as soon as possible after the diagnosis of HF with reduced LVEF [1].